Guardant Health 公布 2024 财年初步销售额约为 7.37 亿美元,比共识值增加 31%

财报速递
13 Jan

2024 全年初步未经审计的财务业绩

  • 总收入约为 7.37 亿美元,增长 31%
  • 报告了大约 206,700 例肿瘤临床测试(不包括 Shield)和大约 40,500 例生物制药测试,分别增长 20% 和 35%

2024 财年第四季度初步未经审计的自由现金流约为负 8400 万美元,2024 全年大约为负 2.75 亿美元。截至 2024 年 12 月 31 日,现金、现金等价物、受限制现金和可售债券为 9.44 亿美元。

"2024 年对 Guardant 来说是出色的一年。我们在整个产品组合中实现了关键里程碑,并完成了 Guardant360 LDT 向我们的智能液体活检平台的升级。我们以 31% 初步全年收入增长强劲结束了这一年,这得益于强劲的临床和生物制药收入以及 Guardant360 ASP 的增加。展望未来,我们相信我们处于有利位置,能够继续推动肿瘤业务的增长,"联合创始人兼联席首席执行官 Helmy Eltoukhy 说道。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10